An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms CheckMate870
- Sponsors Bristol-Myers Squibb
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.
- 06 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 9 Mar 2018.
- 10 Nov 2017 Planned initiation date changed from 26 Oct 2017 to 1 Dec 2017.